APA (7th ed.) Citation

Donaldson, S. H., Pilewski, J. M., Griese, M., Cooke, J., Viswanathan, L., Tullis, E., . . . Wang, L. T. (2018). Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del / F508del-CFTR or F508del / G551D-CFTR. American journal of respiratory and critical care medicine, 197(2), 214-224. https://doi.org/10.1164/rccm.201704-0717OC

Chicago Style (17th ed.) Citation

Donaldson, Scott H., Joseph M. Pilewski, Matthias Griese, Jon Cooke, Lakshmi Viswanathan, Elizabeth Tullis, Jane C. Davies, Julie A. Lekstrom-Himes, and Linda T. Wang. "Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del / F508del-CFTR or F508del / G551D-CFTR." American Journal of Respiratory and Critical Care Medicine 197, no. 2 (2018): 214-224. https://doi.org/10.1164/rccm.201704-0717OC.

MLA (9th ed.) Citation

Donaldson, Scott H., et al. "Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del / F508del-CFTR or F508del / G551D-CFTR." American Journal of Respiratory and Critical Care Medicine, vol. 197, no. 2, 2018, pp. 214-224, https://doi.org/10.1164/rccm.201704-0717OC.